Stocktoria
Editas Medicine, Inc. EDIT
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2016-02-03
Editas Medicine, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $40.5M | $32.3M | $78.1M | $19.7M | $25.5M |
| R&D expense | $90.0M | $199.2M | $177.7M | $175.0M | $142.5M |
| Operating income | -$160.0M | -$251.2M | -$169.2M | -$225.9M | -$193.1M |
| Income tax | $0 | $0 | $0 | $0 | $0 |
| Net income | -$160.1M | -$237.1M | -$153.2M | -$220.4M | -$192.5M |
| EPS (diluted) | $-1.80 | $-2.88 | $-2.02 | $-3.21 | $-2.85 |
| Operating cash flow | -$165.2M | -$210.3M | -$132.2M | -$177.3M | -$163.8M |
| Free cash flow | -$165.8M | -$219.1M | -$136.9M | -$181.5M | -$171.8M |
| Cash & equivalents | $146.6M | $131.5M | $123.7M | $141.5M | $203.5M |
| Total assets | $186.5M | $341.6M | $499.2M | $514.3M | $677.5M |
| Total liabilities | $159.2M | $207.3M | $150.1M | $153.6M | $123.8M |
| Shareholders' equity | $27.3M | $134.3M | $349.1M | $360.7M | $553.6M |
Source: SEC EDGAR filings · CIK 0001650664 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.